HOME >> BIOLOGY >> NEWS
Researchers discover new mechanism that targets and destroys abnormal RNA

c diseases in which mutations cause premature termination of protein production.

A specific example is the testing of drugs called aminoglycosides to treat cystic fibrosis and other diseases caused by premature termination codons, said Dietz. The idea is that these drugs would allow read-through of such codons, to generate adequate levels of full-length functional proteins. Unfortunately, these drugs have not performed very well, he said.

Our studies of the effects of one such drug on yeast indicate that this read-through generates mRNAs that trigger the nonstop decay mechanism to degrade them, said Dietz. This finding offers the promise that drugs that inhibit nonstop decay might enable aminoglycoside drugs to function as effective treatments for some genetic diseases.

Termination codons are present in about one-third of human disease genes, representing literally thousands of genes, said Dietz. So this dual-drug treatment strategy could be relevant to a large number of human disorders, including cystic fibrosis and muscular dystrophy.

In the second Science paper, lead author Ambro van Hoof, in Parkers laboratory, did experiments that revealed the specific cellular machinery that produces nonstop decay. According to Parker, those experiments showed that a multi-enzyme complex called the exosome is important for nonstop decay.

The exosome is a collection of enzymes called exonucleases that snip apart RNA molecules. In their experiments, van Hoof, Parker and their colleagues set out to see if the exosome was involved in nonstop mRNA decay.

It was known that the exosome was involved in a variety of RNA degradation processes in the cell, probably controlled through specific adapters, although we really dont understand the mechanisms well, said Parker. According to Parker, the adapter protein, which is attached to the exosome, somehow recognizes the nonstop RNA and attaches to the ribosome.

Parker, van Hoof
'"/>

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
21-Mar-2002


Page: 1 2 3 4

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
Cached News: